
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics Inc. has established a strong intellectual property position through multiple patent allowances, enhancing market exclusivity and providing a competitive edge for its lead asset, EryDex, indicating potential for long-term commercial success. The company’s compelling safety data supporting EryDex’s efficacy in treating Ataxia-Telangiectasia (A-T) reinforces its transformative potential in patient care, with the possibility of regulatory submissions set for 2026 serving as a significant milestone. With a robust cash position of $47.8 million as of Q3 2024, Quince is well-positioned to advance its clinical programs and achieve key regulatory objectives in the upcoming years.
Bears say
Quince Therapeutics is at a preclinical stage with a drug pipeline focused on rare diseases, which may pose significant risks related to the uncertain timelines and regulatory hurdles associated with drug development. The lack of revenue generation due to its early-stage status raises concerns about the company's financial sustainability, especially given the high costs involved in bringing therapeutic products to market. Additionally, the potential for limited market acceptance and competition within the biopharmaceutical sector further complicates the outlook for Quince Therapeutics' stock performance.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares